Monopar Therapeutics Inc.: Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
Interim Analysis Planned for Q1 2023WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary
Chandler Robinson Kimr Tsuchimoto Exchange Commission Monopar Therapeutics Inc Interim Analysis Planned Validive Phase
Source: finanznachrichten.de